. home.aspx

home.aspx
   

Bayer, Bristol-Myers Squibb and Ono Pharma Team on Colorectal Cancer

July 18, 2019 / MARK TERRY

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical have teamed up to study the most common type of metastatic colorectal cancer (mCRC). The three companies will collaborate to test Bayer’s kinase inhibitor Stivarga (regorafenib) and Bristol-Myers Squibb’s and Ono’s anti-PD-1 checkpoint inhibitor Opdivo (nivolumab) in microsatellite stable metastatic colorectal cancer (MSS mCRC). The effectiveness of immuno-oncology treatments for some subpopulations of CRC have been observed, but about 95% of mCRC have MSS tumors, where immuno-oncology monotherapies haven’t been as effective.

Popular Topics